Abstracts tagged "Clinical"

Abstract Number: 1200 • 2017 ACR/ARHP Annual Meeting
Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo
Philip G. Conaghan¹, Francis Berenbaum², Virginia B. Kraus³, James Johnson⁴ and Scott Kelley⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Pierre & Marie Curie University, Saint-Antoine Hospital, Paris, France, ³Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁴Summit Analytical, Denver, CO, ⁵Flexion Therapeutics, Inc., Burlington, MA
Background/Purpose: A recent meta-analysis concluded that intra-articular corticosteroids (IACS) for knee osteoarthritis (OA) may be associated with moderate improvement in pain compared with control treatment.1,2…
Abstract Number: 1274 • 2017 ACR/ARHP Annual Meeting
Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel⁴, Frederick W Miller² and Lisa G Rider², ¹Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴George Washington University School of Medicine and Health Sciences, Washington, DC
Background/Purpose: Anti-MDA5 autoantibodies (Abs) have been associated with clinically amyopathic and classic dermatomyositis (DM), with rapidly progressive interstitial lung disease (ILD) and poor prognosis in…
Abstract Number: 2633 • 2017 ACR/ARHP Annual Meeting
Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Marika Kvarnstrom¹, Guillermo Ruacho², Johanna Gustafsson³, Agneta Zickert⁴, Vilija Oke⁵, Johan Rönnelid⁶, Kerstin Elvin⁷, Iva Gunnarsson⁸ and Elisabet Svenungsson⁸, ¹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology,, Stockholm, Sweden, ³Dep. of Medicine, Karolinska Institutet, Karolinska University Hospital, Unit of rheumatology,, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Clinical Immunology and Transfusion Medicine,, 4Unit of Clinical Immunology, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose :Sjögren´s syndrome occurs in isolation (primary Sjögren´s syndrome, pSS), but it is also often secondary (sSS) to, and sometimes difficult to delineate from, other…
Abstract Number: 159 • 2016 ACR/ARHP Annual Meeting
Assessing Agreement Among Measures of Inflammation Detected on Magnetic Resonance Imaging, Ultrasound and Clinical Findings in the Feet of Patients with Early Rheumatoid Arthritis
Karen A. Beattie¹, George Ioannidis², Sydney Scheffler³, Saara Totterman⁴, Edward Schreyer⁵ and Maggie Larche¹, ¹Medicine, McMaster University, Hamilton, ON, Canada, ²St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Radiology, VirtualScopics Inc., Rochester, NY, ⁵QMetrics Technologies, Rochester, NY
Background/Purpose: In metatarsalphalangeal (MTP) joints 2-5 of patients with early rheumatoid arthritis (RA), we aimed to assess the agreement between i) Magnetic Resonance Imaging (MRI)…
Abstract Number: 517 • 2016 ACR/ARHP Annual Meeting
Association of Rheumatoid Arthritis Disease Activity and Clinical Profile with Chronic Periodontitis
BEATRIZ RODRIGUEZ-LOZANO¹, Jorge Luis Garnier Rodríguez², Jerián González Febles³, Shashi Dadlani⁴, Ivan Ferraz-Amaro¹, Esmeralda Delgado Frías¹, Federico Díaz-González¹ and Mariano Sanz Alonso³, ¹Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ²Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, ³Periodontology, Universidad Complutense de Madrid, Madrid, Spain, ⁴Periodontology, Dental Clinic Garnier, S/C Tenerife, Spain
Background/Purpose: Recent clinical data show a clear association between periodontitis (P) and RA. However, there is controversy over whether severity of P is associated with…
Abstract Number: 687 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵, ¹Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RAPID-axSpA (NCT01087762) investigated the efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic…
Abstract Number: 1357 • 2016 ACR/ARHP Annual Meeting
Clinical Description of Patients with Cytoplasmic Discrete Speckles on Indirect Immunofluorescence on HEp-2 Cells in a Universitary Hospital
Martin Brom¹, Carolina Eva Carrizo², Roberto Arana³ and Cecilia N. Pisoni³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²CEMIC, Buenos Aires, Argentina, ³Rheumatology and Immunology, CEMIC, Buenos Aires, Argentina
Background/Purpose: Indirect Immunofluorescence (IIF) shows different nuclear and cytoplasmic fluorescence patterns depending on the antibodies present in the cell. Cytoplasmic patterns are an unusual finding.…
Abstract Number: 1805 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Jorge Romo-Tena¹, Diana Gómez-Martín¹, Roberto Reyna², Isaac Bartnicki-Navarrete³ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by disease flares, alternated with periods of clinical remission. In the past years, the “treat-to-target” strategy in SLE…
Abstract Number: 2665 • 2016 ACR/ARHP Annual Meeting
Epratuzumab Treatment of Patients with Systemic Lupus Erythematosus and Secondary Sjogren’s Syndrome: An Exploratory Analysis of Phase 3 Studies
Jacques-Eric Gottenberg¹, Thomas Dörner², Hendrika Bootsma³, Valerie Devauchelle-Pensec⁴, Simon Bowman⁵, Gordana Kosutic⁶, Holger Bartz⁷, Marga Oortgiesen⁶, Anthony Shock⁸, Willem Koetse⁶, Catrinel Galateanu⁹, Sabine Bongardt⁷, Xavier Mariette¹⁰ and Caroline Gordon^11,12, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ⁴Department of Rheumatology and Unit of Immunology, Brest University Medical School, Brest, France, ⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Brussels, Belgium, ¹⁰INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, ¹¹NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ¹²Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The EMBODY 1 (SL0009; NCT01262365) and EMBODY 2 (SL0010; NCT01261793) phase 3 studies investigated the efficacy and safety of epratuzumab (Emab; Immunomedics Inc), a…
Abstract Number: 2801 • 2016 ACR/ARHP Annual Meeting
Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus
Laurence S Magder¹, Ali Duarte-Garcia², Erik Barr³ and Michelle Petri⁴, ¹Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Tufts Medical Center, Boston, MA, ³Epidemiology, University of Maryland, Baltimore, MD, ⁴Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis remains one of the most devastating SLE complications, occurring in over 50% of the patients. It is important to identify clinical conditions…
Abstract Number: 2902 • 2016 ACR/ARHP Annual Meeting
Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group
Zsuzsanna McMahan¹, Tracy M. Frech², Guya Piemonte³, Marco Matucci-Cerinic⁴, Susanna Proudman^5,6, Veronica J. Berrocal⁷, Ron Hays⁸ and Dinesh Khanna⁹, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Florence, Florence, Italy, ⁴Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, ⁵Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁶Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁷Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁸UCLA, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 95% of patients with systemic sclerosis (SSc). There is consensus in the Scleroderma Clinical Trials Consortium (SCTC)…
Abstract Number: 2693 • 2015 ACR/ARHP Annual Meeting
Comparing Eight Year Clinical and Radiographic Outcome in Two Cohorts of Patients with Rheumatoid Arthritis
Maria LE Andersson¹, Kristina Forslind² and Ingiäld Hafström³, ¹R&D Centre Spenshult,Halmstad, Halmstad, Sweden, ²Department of Medicine, Helsingborgs Lasarett, Section of Rheumatology, Helsingborg, Sweden, ³Rheumatology Dept, Karoliska Institute, Stockholm, Sweden
Background/Purpose: To compare patient and disease characteristics over the first 8 years of disease in a large inception cohort of early RA patients included 1992…
Abstract Number: 2938 • 2015 ACR/ARHP Annual Meeting
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Kichul Ko¹, Alana B. Levine², Russell Griffin³, Olga Dvorkina⁴, Saira Sheikh⁵, Jinoos Yazdany⁶, Richard Furie⁷ and Cynthia Aranow⁸, ¹Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, SUNY Health Science Center at Brooklyn, Brooklyn, NY, ⁵University of North Carolina, Chapel Hill, NC, ⁶Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ⁸Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…
Abstract Number: 398 • 2015 ACR/ARHP Annual Meeting
Clinical and Serological Profile of Children with Positive SSA-Ro/SSB-La Antibodies
Juan G. Ovalles-Bonilla¹, Juan C. Nieto¹, Francisco Javier López Longo¹, Julia Martínez-Barrio², Iustina Janta¹, Esperanza Naredo¹, Carlos M. Gonzalez¹, Michelle Hinojosa¹, Natalia Bello¹, Belen Serrano¹, Carmen Mata¹, Claudia Sáenz Tenorio¹, Diana C. Hernández¹, Lara Valor¹, Indalecio Monteagudo¹ and Luis Carreño¹, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Several studies have shown the relationship between anti-SSA-Ro/SSB-La antibodies and Systemic Lupus Erythematosus (SLE), Sjögren Syndrome (SS) and other autoimmune diseases in adult population.…
Abstract Number: 451 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in a Real World Setting Using the Database Jointman
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: Tofacitinib (TFA) was approved for the treatment of rheumatoid arthritis (RA) in November of 2012. It is well accepted that patients studied in pharmaceutically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].